Literature DB >> 32315675

Pulmonary Fibrosis and a TERT Founder Mutation With a Latency Period of 300 Years.

Joanne J van der Vis1, Jasper J van der Smagt2, Frederic A M Hennekam2, Jan C Grutters3, Coline H M van Moorsel3.   

Abstract

BACKGROUND: Germline mutations in the gene encoding TERT cause haploinsufficiency with subsequent telomere shortening. TERT mutations are associated with short telomere syndromes, such as pulmonary fibrosis (PF), which is often the first manifestation of a short telomere syndrome. Telomere length is heritable, and progeny of telomerase mutation carriers are known to have shorter telomeres. In families with TERT mutations, genetic anticipation, the earlier onset of symptoms with successive generation, is described. Little is known on the number of generations that may pass before disease occurs in families with a TERT mutation. RESEARCH QUESTION: The objective of this study was to determine classification and origin of the new TERT c.2005T mutation from population genetics and genealogic data and disease history of affected families. STUDY DESIGN AND METHODS: The TERT gene of 240 patients with familial PF was screened for mutations. Additionally, 1,015 patients with PF, 1,237 patients with an interstitial lung disease (ILD) without PF, and 529 healthy control subjects were genotyped for the TERT c.2005C>T mutation. Genealogic research was performed on all patients who carried the TERT c.2005T mutation.
RESULTS: We detected the TERT c.2005T (p.Arg669Trp) mutation in 13 out of 1,255 patients with PF vs none of the patients with ILD without PF and the healthy control subjects. Genealogic research connected four of the TERT c.2005T mutation carriers to a common ancestor who lived seven generations back, spanning a period of 300 years.
INTERPRETATION: The TERT c.2005T mutation is a pathogenic mutation and associates with PF. This study learns that a latency period of > 300 years may pass before the cumulative effect of telomere shortening eventually leads to PF. This finding underlines the complexity of the clinical interpretation of TERT mutations because, not the presence of the mutation, but the result of genetic anticipation, is associated with disease. Therefore, multidisciplinary discussion between pulmonary physicians, clinical geneticists, and genetic laboratory experts is recommended.
Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  TERT; genetic anticipation; pulmonary fibrosis; short telomere syndrome; telomere shortening

Mesh:

Substances:

Year:  2020        PMID: 32315675     DOI: 10.1016/j.chest.2020.03.069

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

Review 1.  Genetics of human telomere biology disorders.

Authors:  Patrick Revy; Caroline Kannengiesser; Alison A Bertuch
Journal:  Nat Rev Genet       Date:  2022-09-23       Impact factor: 59.581

2.  Utility of Telomerase Gene Mutation Testing in Patients with Idiopathic Pulmonary Fibrosis in Routine Practice.

Authors:  Julij Šelb; Katarina Osolnik; Izidor Kern; Peter Korošec; Matija Rijavec
Journal:  Cells       Date:  2022-01-22       Impact factor: 6.600

3.  Clustering of lung diseases in the family of interstitial lung disease patients.

Authors:  Michelle Terwiel; Jan C Grutters; Coline H M van Moorsel
Journal:  BMC Pulm Med       Date:  2022-04-07       Impact factor: 3.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.